MDXH: יחס שווי שוק להכנסות MDxHealth, Inc.

MDxHealth SA ensures the rapid delivery of urological samples to laboratories while maintaining their quality. The estimated P/S ratio in the GURU.Markets terminal reflects the business value-to-revenue dynamics, where the current level is 0.10. Patents and FDA approval create a high barrier to entry for competitors. The company is implementing DNA genetic tests that allow for the avoidance of unnecessary prostate biopsies.

The expansion of the MDxHealth diagnostic ecosystem and the broadening of Medicare insurance coverage are directly reflected in the price-to-sales ratio. This indicator compares market capitalization to sales volume, allowing investors to determine the premium paid for every dollar of revenue and identify abnormal deviations of the business value from its actual operational growth dynamics.